SPOTLIGHT: Exubera pain grows worse

The pain of dismal Exubera sales is spreading. West Pharmaceutical Services, which makes 60 percent of the inhaler used to deliver the insulin spray, told the Securities and Exchange Commission that it's cutting production in response to lower-than-expected turnover. The highly anticipated Pfizer product only sold $4 million worth during the second quarter. "We expect Pfizer's high inventory levels and slower-than-expected demand will affect our fourth-quarter 2007 and full-year 2008 sales," according to documents filed with the SEC. The filing goes on to state that West has cut production of the inhaler to one shift per day.  Report

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.